Ivacaftor Elpen

Ivacaftor, the active ingredient in Ivacaftor Elpen, is a CFTR potentiator presented as an oral tablet for oral use. It treats cystic fibrosis in patients who carry specific gating mutations of the CFTR gene, improving lung function and reducing disease severity.

GNH USA supplies Ivacaftor Elpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Ivacaftor is a CFTR potentiator used to manage cystic fibrosis caused by specific gating mutations. It works by enhancing chloride transport in affected epithelial cells.

- Cystic fibrosis with G551D mutation: improves pulmonary function and lowers sweat‑chloride levels. - Cystic fibrosis with R117H mutation: enhances airway clearance and reduces exacerbations. - Cystic fibrosis with other approved gating mutations: increases overall respiratory health and quality of life.

Ivacaftor is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: occasional, usually self‑limiting. - Nausea: transient, may improve with food. - Upper respiratory tract infection: mild symptoms. - Abdominal pain: intermittent discomfort. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Elevated liver enzymes: requires monitoring of hepatic function. - Cataracts: especially in pediatric patients, regular eye exams advised. - Severe rash or Stevens‑Johnson syndrome: discontinue if observed. - Arrhythmia: monitor cardiac status in susceptible individuals. - Pulmonary haemorrhage: rare but potentially life‑threatening.

Before initiating therapy, clinicians should consider several safety measures. - Monitor liver function: obtain baseline tests and repeat periodically. - Assess for drug interactions: especially strong CYP3A4 modulators. - Evaluate for cataract development: schedule regular ophthalmologic exams in children. - Avoid use in patients with known hypersensitivity to ivacaftor or its excipients. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Ivacaftor is metabolised primarily by CYP3A4, making it susceptible to pharmacokinetic interactions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase ivacaftor exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.

Moderate Interactions (Monitor Closely): - Hormonal contraceptives: reduced effectiveness, consider alternative methods. - Warfarin: potential alteration of anticoagulant effect, monitor INR. - Digoxin: possible increase in serum levels, observe for toxicity.